Regulation

How Japan regulates regenerative medicine

In Japan, regenerative medicine is not left to general medical practice: it is governed by a dedicated law. This page sets out, in order, the regulatory facts you need before you go.

Checked 2026-11Sources: MHLW and other official or major published sources

01A dedicated law

Japan’s Act on the Safety of Regenerative Medicine (再生医療等の安全性の確保等に関する法律, Act No. 85 of 2013) took effect in November 2014. It governs regenerative medicine provided by medical institutions.

Source: Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); checked 2026-11

02A provision plan comes first

Before offering regenerative medicine, a medical institution must prepare a “provision plan for regenerative medicine”, have it reviewed by a certified committee for regenerative medicine, and submit it to the Ministry of Health, Labour and Welfare (MHLW) through the “e-再生医療” system.

Offering regenerative medicine without completing these steps is illegal in Japan and is penalized.

So the most useful thing to confirm before you go is whether the clinic you are considering has submitted a provision plan for the treatment you want. Send the clinic name to our advisor and we will check whether it has submitted a provision plan.

Source: Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); checked 2026-11

03Three classes by risk

The Act sorts regenerative medicine by risk into Class I (high risk), Class II (medium risk) and Class III (low risk). Two kinds of committee carry out the review: a “Specially Certified Committee for Regenerative Medicine”, and a “Certified Committee for Regenerative Medicine” that reviews Class III only.

The table shows how treatments generally map to the classes. The class of a specific treatment is whatever the clinic’s submitted plan states.

ClassRiskGenerally includesReview committee
Class IHigh riskiPS cells, ES cells and similarSpecially Certified Committee for Regenerative Medicine
Class IIMedium riskThe patient’s own somatic stem cells (e.g. adipose-derived stem cells)Specially Certified Committee for Regenerative Medicine
Class IIILow riskSomatic cell processing without stem cells (e.g. immune cell therapy); PRP for dental and similar uses mostly falls hereCertified Committee for Regenerative Medicine

Source: Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); MHLW division notice, risk-classification chart; checked 2026-11

04The 2025 amendment covers in vivo gene therapy

On 31 May 2025 the amended Act (Act No. 51 of 2024) took effect, bringing in vivo gene therapy that does not use processed cells under the Act as well.

Source: Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); checked 2026-11

05An information and reporting window, 2026

On 2 September 2026 the MHLW opened an information and reporting window for regenerative medicine, which takes reports of illegal practice or safety concerns.

Source: Ministry of Health, Labour and Welfare (MHLW), "再生医療・細胞医療・遺伝子治療について" (Regenerative, cell and gene therapy); checked 2026-11

06First conditional approvals for iPS cell-derived products

On 6 March 2026 the MHLW granted conditional, time-limited (7-year) approval to Sumitomo Pharma’s iPS cell-derived product for Parkinson’s disease (アムシェプリ) and to Cuorips’ product for severe heart failure (リハート). These are the first iPS cell-derived products to be approved.

After conditional approval, post-marketing surveillance of every treated case is still required before full approval can be applied for.

Source: Science Portal (JST), 18 March 2026; Sumitomo Pharma announcement; checked 2026-11

The information on this site is general information and is not medical advice; whether any therapy suits you can only be decided by a doctor after an in-person consultation. Regulatory details are as published by the MHLW.
One-to-one advice

Still unsure? Ask an advisor

Use the “Chat with an advisor” button on this page (at the bottom of the screen on mobile, bottom right on desktop) to open a chat with the Stem Cell Japan advice desk.

Chat with an advisor